ADVERTISEMENT

Clinical Summary

Olaparib for BRCA1/2-mutated early breast cancer

Miriam Davis, PhD   |   28 October 2022

Takeaway

  • 4-year survival data from the OlympiA trial of olaparib showed superiority over placebo for high-risk human epidermal growth factor receptor 2-negative early breast cancer in women with pathogenic variants or likely pathogenic variants in germline  BRCA1  or  BRCA2  genes (g BRCA1/2 pv).

Why this matters

  • This is the second...

          

November Challenge

Ends in 11h
left
right

Topic Challenges

left
right